BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

Company Overview

BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology indications. The company uses an artificial intelligence-driven drug development platform to identify and advance therapies by analyzing existing clinical and biomedical data, with the goal of improving the efficiency of drug discovery and development.

BioXcel’s primary commercial product is IGALMI (dexmedetomidine) sublingual film, which the U.S. Food and Drug Administration approved in 2022 for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. The product is designed for administration under the tongue and is intended for use in a monitored healthcare setting.

BioXcel Therapeutics is headquartered in New Haven, Connecticut, and has focused its clinical and commercial activities primarily on the U.S. market. The company was led by co-founder and Chief Executive Officer Vimal Mehta, who has overseen its efforts to develop AI-enabled therapies and expand the use of its neuroscience-focused product portfolio.

Key Stats

• Today's Range: $0.07 to $0.09
• 50-Day Range: $0.07 to $1.19
• 52-Week Range: $0.07 to $4.29
• Volume: 42.29 million shs
• Average Volume: 17.36 million shs
• Market Capitalization: $2.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Hold

BioXcel Therapeutics Stock Analysis - MarketRank™

BioXcel Therapeutics scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

BioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

BioXcel Therapeutics has a consensus price target of $11.00, representing about 14,744.8% upside from its current price of $0.07.

Amount of Analyst Coverage

BioXcel Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.70) to ($2.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioXcel Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioXcel Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.32% of the float of BioXcel Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

BioXcel Therapeutics has a short interest ratio ("days to cover") of 0.85, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioXcel Therapeutics has recently increased by 84.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioXcel Therapeutics does not currently pay a dividend.

Dividend Growth

BioXcel Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for BioXcel Therapeutics this week, compared to 2 articles on an average week.

Search Interest

11 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.70% of the stock of BioXcel Therapeutics is held by insiders.

Percentage Held by Institutions

30.68% of the stock of BioXcel Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BTAI
• CIK: 1720893
• Web: www.bioxceltherapeutics.com
• Phone: (475) 238-6837
• Fax: N/A
• Employees: 90
• Year Founded: 2017

Price Target and Rating

• Average Price Target for BioXcel Therapeutics: $11.00
• High Price Target: $17.00
• Low Price Target: $5.00
• Potential Upside/Downside: +14,744.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.90 million
• Net Margins: -9,549.87%
• Pretax Margin: -9,549.87%
• Return on Equity: N/A
• Return on Assets: -185.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.21
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: $640 thousand
• Price / Sales: 3.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.37) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 31,310,000
• Free Float: 30,148,000
• Market Cap: $2.32 million
• Optionable: No Data
• Beta: 0.19